Drugs in the Pipeline
Phase 3 Study Update of Tofacitinib for Rheumatoid Arthritis
Pfizer announced results from two of its Phase 3 studies, ORAL Standard and Oral Step, of tofacitinib (CP-690,550) for the treatment of active rheumatoid arthritis.